Survival after Long-Term ART Exposure: Findings from an Asian Patient Population Retained in Care beyond 5 Years on ART
Background This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort. Methods We included patients in follow-up >5 years after ART initiation. Factors associated with mortality bey...
Gespeichert in:
| Veröffentlicht in: | Antiviral therapy 2020-01, Vol.25 (3), p.131-142 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 142 |
|---|---|
| container_issue | 3 |
| container_start_page | 131 |
| container_title | Antiviral therapy |
| container_volume | 25 |
| creator | Bijker, Rimke Kiertiburanakul, Sasisopin Kumarasamy, Nagalingeswaran Pujari, Sanjay Sun, Ly P Ng, Oon T Lee, Man P Choi, Jun Y Nguyen, Kinh V Chan, Yu J Merati, Tuti P Cuong, Do D Ross, Jeremy Jiamsakul, Awachana |
| description | Background
This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort.
Methods
We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ART were analysed using competing risk regression with time-updated variables.
Results
Of 13,495 patients retained after 5 years on ART, 279 subsequently died (0.56/100 person-years). Increased mortality was associated with age >50 years (sub-hazard ratio [sHR] 2.24, 95% CI 1.58, 3.15, compared with ≤40 years), HIV exposure through injecting drug use (sHR 2.17, 95% CI 1.32, 3.56), HIV viral load ≥1,000 copies/ml: sHR 1.52, 95% CI 1.05, 2.21, compared with |
| doi_str_mv | 10.3851/IMP3358 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_journals_2478820954</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.3851_IMP3358</sage_id><sourcerecordid>2398616384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-227525530b48537d6669e3c2efed1516c487fb79084f6b11801537fca2ba174b3</originalsourceid><addsrcrecordid>eNpd0d9r2zAQB3AxWpY0G_sPhqCF9sWbfliy3LcQkq6QstBlD3sysn0OCraUSnbb_PdVSdZCX3R6-PC94w6hb5T84ErQn7d3K86F-oTGjKQkYUSoEzSmXOSJFFyM0FkIW0KYygn5jEaccZlHOEZPfwb_aB51i3XTg8dLZzfJGnyHp_drPH_euTB4uMYLY2tjNwE33nVYWzwNJr4r3RuwPV653dDGv7P4HnptLNTYWDzTHnAJe2drLPA_0D7gSGL0F3Ta6DbA12OdoL-L-Xr2K1n-vrmdTZdJxTPaJ4xlggnBSZkqwbNaSpkDrxg0UFNBZZWqrCmznKi0kSWlitDImkqzUtMsLfkEXR1yd949DBD6ojOhgrbVFtwQCsZzJankKo30_APdusHbOF3B0kwpRnLxqi4PqvIuBA9NsfOm035fUFK83qI43iLK78e8oeygfnP_lx_BxQEEvYH3Zh9zXgBSDIxW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2478820954</pqid></control><display><type>article</type><title>Survival after Long-Term ART Exposure: Findings from an Asian Patient Population Retained in Care beyond 5 Years on ART</title><source>Sage Journals GOLD Open Access 2024</source><creator>Bijker, Rimke ; Kiertiburanakul, Sasisopin ; Kumarasamy, Nagalingeswaran ; Pujari, Sanjay ; Sun, Ly P ; Ng, Oon T ; Lee, Man P ; Choi, Jun Y ; Nguyen, Kinh V ; Chan, Yu J ; Merati, Tuti P ; Cuong, Do D ; Ross, Jeremy ; Jiamsakul, Awachana</creator><creatorcontrib>Bijker, Rimke ; Kiertiburanakul, Sasisopin ; Kumarasamy, Nagalingeswaran ; Pujari, Sanjay ; Sun, Ly P ; Ng, Oon T ; Lee, Man P ; Choi, Jun Y ; Nguyen, Kinh V ; Chan, Yu J ; Merati, Tuti P ; Cuong, Do D ; Ross, Jeremy ; Jiamsakul, Awachana ; IeDEA Asia-Pacific ; Asia-Pacific IeDEA</creatorcontrib><description>Background
This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort.
Methods
We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ART were analysed using competing risk regression with time-updated variables.
Results
Of 13,495 patients retained after 5 years on ART, 279 subsequently died (0.56/100 person-years). Increased mortality was associated with age >50 years (sub-hazard ratio [sHR] 2.24, 95% CI 1.58, 3.15, compared with ≤40 years), HIV exposure through injecting drug use (sHR 2.17, 95% CI 1.32, 3.56), HIV viral load ≥1,000 copies/ml: sHR 1.52, 95% CI 1.05, 2.21, compared with <400), regimen (second-line regimen: sHR 2.11, 95% CI 1.52, 2.94, and third-line regimen: sHR 2.82, 95% CI 2.00, 3.98, compared with first-line regimen), HBV coinfection (sHR 2.23, 95% CI 1.49, 3.33), fasting plasma glucose ≥126 mg/dl (sHR 1.98, 95% CI 1.22, 3.21, compared with <100 mg/dl) and estimated glomerular filtration rate <60 ml/min/1.73 m2 (sHR 2.57, 95% CI 1.56, 4.22). Decreased mortality was associated with transmission through male-to-male sexual contact (sHR 0.44, 95% CI 0.22, 0.88, compared with heterosexual transmission) and higher CD4+ T-cell count (200–349 cells/μl: sHR 0.27, 95% CI 0.20, 0.38, 350–499 cells/μl: sHR 0.10, 95% CI 0.07, 0.16 and ≥500 cells/μl: sHR 0.09, 95% CI 0.06, 0.13, compared with <200 cells/μl). Results after 10 years were similar, but most associations were weaker due to limited power.
Conclusions
Next to preventing ART failure, HIV programmes should carefully monitor and treat comorbidi-ties, including hepatitis, kidney disease and diabetes, to optimize survival after long-term ART exposure.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.3851/IMP3358</identifier><identifier>PMID: 32369040</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Antiretroviral therapy ; CD4 antigen ; Diabetes mellitus ; Disease transmission ; Glomerular filtration rate ; Hepatitis ; HIV ; Human immunodeficiency virus ; Kidney diseases ; Lymphocytes T ; Mortality</subject><ispartof>Antiviral therapy, 2020-01, Vol.25 (3), p.131-142</ispartof><rights>2020 SAGE Publications</rights><rights>Copyright International Medical Press 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-227525530b48537d6669e3c2efed1516c487fb79084f6b11801537fca2ba174b3</citedby><cites>FETCH-LOGICAL-c371t-227525530b48537d6669e3c2efed1516c487fb79084f6b11801537fca2ba174b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.3851/IMP3358$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.3851/IMP3358$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21966,27853,27924,27925,44945,45333</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.3851/IMP3358?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32369040$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bijker, Rimke</creatorcontrib><creatorcontrib>Kiertiburanakul, Sasisopin</creatorcontrib><creatorcontrib>Kumarasamy, Nagalingeswaran</creatorcontrib><creatorcontrib>Pujari, Sanjay</creatorcontrib><creatorcontrib>Sun, Ly P</creatorcontrib><creatorcontrib>Ng, Oon T</creatorcontrib><creatorcontrib>Lee, Man P</creatorcontrib><creatorcontrib>Choi, Jun Y</creatorcontrib><creatorcontrib>Nguyen, Kinh V</creatorcontrib><creatorcontrib>Chan, Yu J</creatorcontrib><creatorcontrib>Merati, Tuti P</creatorcontrib><creatorcontrib>Cuong, Do D</creatorcontrib><creatorcontrib>Ross, Jeremy</creatorcontrib><creatorcontrib>Jiamsakul, Awachana</creatorcontrib><creatorcontrib>IeDEA Asia-Pacific</creatorcontrib><creatorcontrib>Asia-Pacific IeDEA</creatorcontrib><title>Survival after Long-Term ART Exposure: Findings from an Asian Patient Population Retained in Care beyond 5 Years on ART</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>Background
This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort.
Methods
We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ART were analysed using competing risk regression with time-updated variables.
Results
Of 13,495 patients retained after 5 years on ART, 279 subsequently died (0.56/100 person-years). Increased mortality was associated with age >50 years (sub-hazard ratio [sHR] 2.24, 95% CI 1.58, 3.15, compared with ≤40 years), HIV exposure through injecting drug use (sHR 2.17, 95% CI 1.32, 3.56), HIV viral load ≥1,000 copies/ml: sHR 1.52, 95% CI 1.05, 2.21, compared with <400), regimen (second-line regimen: sHR 2.11, 95% CI 1.52, 2.94, and third-line regimen: sHR 2.82, 95% CI 2.00, 3.98, compared with first-line regimen), HBV coinfection (sHR 2.23, 95% CI 1.49, 3.33), fasting plasma glucose ≥126 mg/dl (sHR 1.98, 95% CI 1.22, 3.21, compared with <100 mg/dl) and estimated glomerular filtration rate <60 ml/min/1.73 m2 (sHR 2.57, 95% CI 1.56, 4.22). Decreased mortality was associated with transmission through male-to-male sexual contact (sHR 0.44, 95% CI 0.22, 0.88, compared with heterosexual transmission) and higher CD4+ T-cell count (200–349 cells/μl: sHR 0.27, 95% CI 0.20, 0.38, 350–499 cells/μl: sHR 0.10, 95% CI 0.07, 0.16 and ≥500 cells/μl: sHR 0.09, 95% CI 0.06, 0.13, compared with <200 cells/μl). Results after 10 years were similar, but most associations were weaker due to limited power.
Conclusions
Next to preventing ART failure, HIV programmes should carefully monitor and treat comorbidi-ties, including hepatitis, kidney disease and diabetes, to optimize survival after long-term ART exposure.</description><subject>Antiretroviral therapy</subject><subject>CD4 antigen</subject><subject>Diabetes mellitus</subject><subject>Disease transmission</subject><subject>Glomerular filtration rate</subject><subject>Hepatitis</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Kidney diseases</subject><subject>Lymphocytes T</subject><subject>Mortality</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpd0d9r2zAQB3AxWpY0G_sPhqCF9sWbfliy3LcQkq6QstBlD3sysn0OCraUSnbb_PdVSdZCX3R6-PC94w6hb5T84ErQn7d3K86F-oTGjKQkYUSoEzSmXOSJFFyM0FkIW0KYygn5jEaccZlHOEZPfwb_aB51i3XTg8dLZzfJGnyHp_drPH_euTB4uMYLY2tjNwE33nVYWzwNJr4r3RuwPV653dDGv7P4HnptLNTYWDzTHnAJe2drLPA_0D7gSGL0F3Ta6DbA12OdoL-L-Xr2K1n-vrmdTZdJxTPaJ4xlggnBSZkqwbNaSpkDrxg0UFNBZZWqrCmznKi0kSWlitDImkqzUtMsLfkEXR1yd949DBD6ojOhgrbVFtwQCsZzJankKo30_APdusHbOF3B0kwpRnLxqi4PqvIuBA9NsfOm035fUFK83qI43iLK78e8oeygfnP_lx_BxQEEvYH3Zh9zXgBSDIxW</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Bijker, Rimke</creator><creator>Kiertiburanakul, Sasisopin</creator><creator>Kumarasamy, Nagalingeswaran</creator><creator>Pujari, Sanjay</creator><creator>Sun, Ly P</creator><creator>Ng, Oon T</creator><creator>Lee, Man P</creator><creator>Choi, Jun Y</creator><creator>Nguyen, Kinh V</creator><creator>Chan, Yu J</creator><creator>Merati, Tuti P</creator><creator>Cuong, Do D</creator><creator>Ross, Jeremy</creator><creator>Jiamsakul, Awachana</creator><general>SAGE Publications</general><general>International Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20200101</creationdate><title>Survival after Long-Term ART Exposure: Findings from an Asian Patient Population Retained in Care beyond 5 Years on ART</title><author>Bijker, Rimke ; Kiertiburanakul, Sasisopin ; Kumarasamy, Nagalingeswaran ; Pujari, Sanjay ; Sun, Ly P ; Ng, Oon T ; Lee, Man P ; Choi, Jun Y ; Nguyen, Kinh V ; Chan, Yu J ; Merati, Tuti P ; Cuong, Do D ; Ross, Jeremy ; Jiamsakul, Awachana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-227525530b48537d6669e3c2efed1516c487fb79084f6b11801537fca2ba174b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antiretroviral therapy</topic><topic>CD4 antigen</topic><topic>Diabetes mellitus</topic><topic>Disease transmission</topic><topic>Glomerular filtration rate</topic><topic>Hepatitis</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Kidney diseases</topic><topic>Lymphocytes T</topic><topic>Mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bijker, Rimke</creatorcontrib><creatorcontrib>Kiertiburanakul, Sasisopin</creatorcontrib><creatorcontrib>Kumarasamy, Nagalingeswaran</creatorcontrib><creatorcontrib>Pujari, Sanjay</creatorcontrib><creatorcontrib>Sun, Ly P</creatorcontrib><creatorcontrib>Ng, Oon T</creatorcontrib><creatorcontrib>Lee, Man P</creatorcontrib><creatorcontrib>Choi, Jun Y</creatorcontrib><creatorcontrib>Nguyen, Kinh V</creatorcontrib><creatorcontrib>Chan, Yu J</creatorcontrib><creatorcontrib>Merati, Tuti P</creatorcontrib><creatorcontrib>Cuong, Do D</creatorcontrib><creatorcontrib>Ross, Jeremy</creatorcontrib><creatorcontrib>Jiamsakul, Awachana</creatorcontrib><creatorcontrib>IeDEA Asia-Pacific</creatorcontrib><creatorcontrib>Asia-Pacific IeDEA</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Bijker, Rimke</au><au>Kiertiburanakul, Sasisopin</au><au>Kumarasamy, Nagalingeswaran</au><au>Pujari, Sanjay</au><au>Sun, Ly P</au><au>Ng, Oon T</au><au>Lee, Man P</au><au>Choi, Jun Y</au><au>Nguyen, Kinh V</au><au>Chan, Yu J</au><au>Merati, Tuti P</au><au>Cuong, Do D</au><au>Ross, Jeremy</au><au>Jiamsakul, Awachana</au><aucorp>IeDEA Asia-Pacific</aucorp><aucorp>Asia-Pacific IeDEA</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival after Long-Term ART Exposure: Findings from an Asian Patient Population Retained in Care beyond 5 Years on ART</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>25</volume><issue>3</issue><spage>131</spage><epage>142</epage><pages>131-142</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>Background
This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort.
Methods
We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ART were analysed using competing risk regression with time-updated variables.
Results
Of 13,495 patients retained after 5 years on ART, 279 subsequently died (0.56/100 person-years). Increased mortality was associated with age >50 years (sub-hazard ratio [sHR] 2.24, 95% CI 1.58, 3.15, compared with ≤40 years), HIV exposure through injecting drug use (sHR 2.17, 95% CI 1.32, 3.56), HIV viral load ≥1,000 copies/ml: sHR 1.52, 95% CI 1.05, 2.21, compared with <400), regimen (second-line regimen: sHR 2.11, 95% CI 1.52, 2.94, and third-line regimen: sHR 2.82, 95% CI 2.00, 3.98, compared with first-line regimen), HBV coinfection (sHR 2.23, 95% CI 1.49, 3.33), fasting plasma glucose ≥126 mg/dl (sHR 1.98, 95% CI 1.22, 3.21, compared with <100 mg/dl) and estimated glomerular filtration rate <60 ml/min/1.73 m2 (sHR 2.57, 95% CI 1.56, 4.22). Decreased mortality was associated with transmission through male-to-male sexual contact (sHR 0.44, 95% CI 0.22, 0.88, compared with heterosexual transmission) and higher CD4+ T-cell count (200–349 cells/μl: sHR 0.27, 95% CI 0.20, 0.38, 350–499 cells/μl: sHR 0.10, 95% CI 0.07, 0.16 and ≥500 cells/μl: sHR 0.09, 95% CI 0.06, 0.13, compared with <200 cells/μl). Results after 10 years were similar, but most associations were weaker due to limited power.
Conclusions
Next to preventing ART failure, HIV programmes should carefully monitor and treat comorbidi-ties, including hepatitis, kidney disease and diabetes, to optimize survival after long-term ART exposure.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>32369040</pmid><doi>10.3851/IMP3358</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1359-6535 |
| ispartof | Antiviral therapy, 2020-01, Vol.25 (3), p.131-142 |
| issn | 1359-6535 2040-2058 |
| language | eng |
| recordid | cdi_proquest_journals_2478820954 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Antiretroviral therapy CD4 antigen Diabetes mellitus Disease transmission Glomerular filtration rate Hepatitis HIV Human immunodeficiency virus Kidney diseases Lymphocytes T Mortality |
| title | Survival after Long-Term ART Exposure: Findings from an Asian Patient Population Retained in Care beyond 5 Years on ART |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T06%3A00%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20after%20Long-Term%20ART%20Exposure:%20Findings%20from%20an%20Asian%20Patient%20Population%20Retained%20in%20Care%20beyond%205%20Years%20on%20ART&rft.jtitle=Antiviral%20therapy&rft.au=Bijker,%20Rimke&rft.aucorp=IeDEA%20Asia-Pacific&rft.date=2020-01-01&rft.volume=25&rft.issue=3&rft.spage=131&rft.epage=142&rft.pages=131-142&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.3851/IMP3358&rft_dat=%3Cproquest_AFRWT%3E2398616384%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2478820954&rft_id=info:pmid/32369040&rft_sage_id=10.3851_IMP3358&rfr_iscdi=true |